Thanks for all the replies. I suppose I am interested particularly in the changing mix of revenue going forward in Japan as lani starts to replace relenza. I hope it is at least as good % royalty as relenza but had only seen the "undisclosed royalty on sales and a number of fixed sum payments on the achievement of certain sales milestones" quote and can only guess whether an increase in lani over relenza is good/bad or indifferent. Agree this may be being kept confidential at the moment due to ROW negiotations.
I'm happy going forward at the moment with tamiflu resistence/interactions improving relenza sales.
BTA Price at posting:
$2.05 Sentiment: LT Buy Disclosure: Held
